Amphastar Pharmaceuticals announced that its Board of Directors expanded the board from 10 to 11 members and appointed Anthony Pierce as a new Class III director, effective July 9, 2026. Pierce was deemed independent under Nasdaq rules and will hold office until the 2028 annual meeting. He has not been assigned to any board committees at this time.

View Full Filing (SEC EDGAR)

2026-07-08

No AI summary for this filing type

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding AMPHASTAR PHARMACEUTICALS IN (AMPH)?

Major stakeholders currently include BlackRock, Inc. ($106.2M), Dimensional Fund Advisors LP ($39.7M), State Street CORP ($31.5M). Based on the latest 13F filings, there are a total of 214 tracked investment funds and institutions maintaining positions in AMPH.

What is the overall institutional sentiment toward AMPH recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $264.3M, driven by 90 managers accumulating shares while 140 reduced their exposure.

Which institutions have been selling or reducing their AMPH positions?

In the latest period, 95 funds trimmed their holdings, and 45 managers completely exited their positions. The aggregate reported sell value was $480.6M.

Are there any notable investors adding AMPH to their portfolios?

Yes, buying activity remains notable. 22 institutions opened new positions in {ticker}, and 68 existing holders added to their shares. The total reported buy value for the quarter amounted to $309.1M.